Developing innovative treatments for genitourinary tract disorders

IXALTIS is a specialty pharmaceutical company developing proprietary therapeutics to treat genitourinary (GU) disorders with unsatisfied medical need. The company was born from the combined expertise of leading scientists specialised in this field and of experienced managers.  IXALTIS has already obtained an exclusive worldwide license for three molecules from SANOFI (IXA-001, IXA-002 and IXA-003).  IXALTIS has established a proprietary position covering IXA-001 for use in urogenital and other disorders based on its specific mechanism of action.

« Our company has the objective of becoming a leading developer of innovative pharmaceutical products for treating disorders of the urogenital tract, bringing to the clinic solutions for diseases that affect many people and for which there are few or no satisfactory treatments ».

Our Objective

Our Objective

Develop innovating treatments for genitourinary tract disorders.

Our team

Our team

Combining world class scientific, managerial and entrepreneurial expertise.

Our pipeline

Our pipeline

3 clinical compounds licensed from Sanofi kick start the development of the company.
LATEST NEWS

Press release, May 2016

Bref, June 2016

Eco des Savoie, June 2016

24H, June 2016

FierceBiotech, June 2016

   

Capital Finance, June 2016